摘要
慢性淋巴细胞白血病(CLL)是由某种肿瘤细胞的无性系种群的积累和增殖所导致的一种临床上的异质性疾病,这种肿瘤细胞在形态上与血液、骨髓和淋巴器官中成熟的小B淋巴细胞相似。CD49d,这条整合的异源二聚体α4β1的 α链,是慢性淋巴细胞白血病细胞与辅助细胞在微环境的主要耦合子,也是测量总生存数的一个主要指标。特别的是,据知CD49d在调整慢性淋巴细胞白血病相关组织中细胞-细胞和细胞-基质相互作用起着关键作用,最终它会释放促存活信号来保护CLL细胞免受药物引发的伤害。以整合素α4β1为靶点的治疗方法可能会在CLL中表现出一种有趣的选择。在以前的实验中,抗-CD49d与那他珠单抗抗体重组后,与细胞毒性药物和利妥昔单抗在体外(的实验)相比,表现出克服基质细胞诱发B淋巴细胞耐药的可能性。此外,CD49d分子引起人们特别的关注,因为从最近被提出的激酶抑制剂的临床活性到BCR都与整合素α4β1的内外活动有所联系。在这篇综述中,我们详细说明了CD49d在CLL细胞中的作用,包括临床影响,特定细胞遗传学特征的关系和负责成长与存活支持信号的淋巴结与骨髓微环境之间依赖于CD49d并最终影响CLL诊断和治疗选择的相互作用。
关键词: 整合的异源二聚体α4β1的 α链,慢性淋巴细胞白血病,微环境,诊断,治疗
图形摘要
Current Cancer Drug Targets
Title:Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
Volume: 16 Issue: 8
Author(s): Michele Dal Bo, Erika Tissino, Dania Benedetti, Chiara Caldana, Riccardo Bomben, Giovanni Del Poeta, Gianluca Gaidano and Francesca Maria Rossi, Pietro Bulian, Antonella Zucchetto, Valter Gattei
Affiliation:
关键词: 整合的异源二聚体α4β1的 α链,慢性淋巴细胞白血病,微环境,诊断,治疗
摘要: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of neoplastic cells with the morphological appearance of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. CD49d, the α chain of the α4β1 integrin heterodimer, is one of the main interactors between CLL cells and accessory cells in the microenvironmental sites and one of the main predictors of overall survival. In particular, CD49d is known to play a pivotal role in mediating both cell-cell and cell-matrix interactions in CLL-involved tissues eventually delivering prosurvival signals and protecting CLL cells from drug-induced damages. Treatment strategies targeting the α4β1 integrin could represent an interesting option in CLL. In this context, the recombinant anti-CD49d antibody natalizumab demonstrated the potential to overcome stromal cell-induced resistance of B cell lymphoma cells against cytotoxic drugs and rituximab in vitro. Moreover, a specific interest for the CD49d molecule raises from the clinical activity of the recently proposed inhibitors of kinases downstream the BCR that has been recently related with the inside-out activation of the α4β1 integrin. In the review, we addressed in detail the role of CD49d in CLL cells, including clinical impact, relationship with specific cytogenetic features, and CD49d-dependent interactions in lymph node and bone marrow microenvironment responsible for growth- and survival- supporting signals, eventually influencing CLL prognosis and therapeutic options.
Export Options
About this article
Cite this article as:
Michele Dal Bo, Erika Tissino, Dania Benedetti, Chiara Caldana, Riccardo Bomben, Giovanni Del Poeta, Gianluca Gaidano and Francesca Maria Rossi, Pietro Bulian, Antonella Zucchetto, Valter Gattei , Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia, Current Cancer Drug Targets 2016; 16 (8) . https://dx.doi.org/10.2174/1568009616666160809102219
DOI https://dx.doi.org/10.2174/1568009616666160809102219 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry Update to: The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?
Medicinal Chemistry Reviews - Online (Discontinued) The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry